China Medical System Holdings Limited China Medical System Holdings Limited

China Medical System Holdings Limited

0867

Hisse Senetlerindeki Sıralama #4722
Established in 1995 and headquartered in North Point, Hong Kong, China Medical... Established in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited functions as an investment holding company with a primary focus on the development, marketing, and distribution of a wide array of pharmaceutical products throughout the People's Republic of China. The company's extensive portfolio addresses numerous therapeutic areas. Its cardiovascular offerings include Plendil for hypertension and stable angina, XinHuoSu for acute heart failure, and Imdur for coronary heart disease, chronic heart failure, and myocardial infarction prevention. For mental health and neurological support, it provides Deanxit to treat mild-to-moderate depression and anxiety, along with Parlodel tablets for endocrine and neuro system indications. Digestive and liver conditions are managed with products such as Ursofalk for gallstones and cholestatic liver disease, Salofalk for ulcerative colitis and Crohn's disease, Bioflor for diarrhea, Combizym for dyspepsia, and Ganfule capsules for primary liver cancer, plus MOVICOL for chronic constipation. The company also markets Augentropfen Stulln Mono eye drops for senile macula degeneration and asthenopia, Hirudoid for blunt trauma and superficial phlebitis, Elcatonin injection for osteoporosis, and Lamisil tablets for fungal infections. Respiratory issues are addressed by YiNuoShu, while infectious diseases benefit from DanShenTong capsules (for various infections like acne, tonsillitis, and boils) and YinlianQinggan granules for hepatitis. XiDaKang, a protein hydrolysate oral solution, is also part of its offerings. Beyond its pharmaceutical endeavors, the group is also actively involved in agriculture and livestock operations. China Medical System Holdings Limited operates as a subsidiary of Treasure Sea Limited.
Hisse Fiyatı
$1.31
Piyasa Değeri
$3.19B
Değişim (1 gün)
-1.25%
Değişim (1 yıl)
-22.74%
Ülke
HK
Ticaret China Medical System Holdings Limited (0867)

Kategori

Healthcare
China Medical System Holdings Limited (0867) için gelir
Jun 2026 itibarıyla gelir TTM: $1.25B
China Medical System Holdings Limited şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $1.25B'dir. 2023 yılında şirketin geliri $1.13B önceki yıla göre azalma 2022 yılındaki $1.33B gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
China Medical System Holdings Limited için 2006 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
Yıl Gelir Değiştir
2026 (TTM) $1.25B 22.48%
2024 $1.02B -9.61%
2023 $1.13B -14.66%
2022 $1.33B 1.13%
2021 $1.31B 23.37%
2020 $1.06B 21.90%
2019 $872.23M 10.42%
2018 $789.91M -3.92%
2017 $822.11M 16.47%
2016 $705.87M 29.00%
2015 $547.21M 15.08%
2014 $475.48M 31.01%
2013 $362.92M 28.63%
2012 $282.14M 34.51%
2011 $209.75M 57.92%
2010 $132.82M 37.69%
2009 $96.46M 32.86%
2008 $72.60M 40.24%
2007 $51.77M 37.69%
2006 $37.60M 0.00%
Benzer şirketler veya rakiplerin geliri